Comparative Pharmacology
Head-to-head clinical analysis: VIVACAINE versus XYLOCAINE VISCOUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VIVACAINE versus XYLOCAINE VISCOUS.
VIVACAINE vs XYLOCAINE VISCOUS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
VIVACAINE is a local anesthetic that blocks the generation and conduction of nerve impulses by decreasing sodium ion permeability across the neuronal membrane.
Lidocaine is an amide-type local anesthetic that blocks voltage-gated sodium channels, inhibiting nerve impulse propagation and reducing pain sensation.
5-10 mL of 1% solution (50-100 mg) via submucosal infiltration or nerve block; maximum 500 mg per procedure.
Adults: 5-15 mL orally (or swish and spit) 4-6 times daily, not to exceed 4 doses in 12 hours or 30 mL in 12 hours.
None Documented
None Documented
Terminal elimination half-life: 6–8 hours in healthy adults. In patients with hepatic impairment, half-life may be prolonged up to 12–15 hours; in severe renal impairment (CrCl <30 mL/min), half-life may extend to 10–12 hours.
Terminal elimination half-life: 1.5-2 hours in adults; prolonged in hepatic impairment or heart failure (up to 6-8 hours). In neonates, half-life may be 3-6 hours due to immature metabolism.
Renal excretion of unchanged drug and metabolites accounts for approximately 85–90% of elimination, with about 10–15% excreted in feces via biliary clearance. Less than 2% of the dose is recovered unchanged in urine; the remainder is as glucuronide conjugates and other metabolites.
Renal excretion of metabolites: ~90%. Unchanged drug: <10%. Biliary/fecal: minor.
Category C
Category C
Local Anesthetic
Local Anesthetic